Clinical-liver, pancreas, and biliary tractPatients with elevated liver enzymes are not at higher risk for statin hepatotoxicity☆
Section snippets
Patients
The Institutional Review Board at Indiana University School of Medicine has approved and administered this study in concordance with the principles of the Declaration of Helsinki. Data were collected from a large academic medical practice located in Indianapolis, which uses the Regenstrief Medical Record System (RMRS).14 This practice-based electronic record system captures patient information from 3 hospitals on the Indiana University Medical Center campus (Wishard Memorial Hospital, Indiana
Results
Cohort 1 contained 342 patients; cohort 2 contained 1437 patients; and cohort 3 contained 2245 patients. Demographics and selected characteristics of these 3 cohorts are shown in Table 1. Although there were some statistical differences in the demographics among the 3 groups, they did not appear to be clinically significant. Generally, all 3 cohorts consisted of a hyperlipidemic, middle-aged population with a female and white preponderance. Although the body weight, LDL, HDL, and creatinine
Discussion
To our knowledge, this is the first study to specifically address the question of whether patients with elevated baseline liver enzymes are at higher risk to develop hepatotoxicity from statins. In this study, we have addressed this question by comparing the changes in liver biochemistries of individuals with elevated liver enzymes and who were prescribed statins to controls. We found that patients with elevated baseline liver enzymes had higher incidence of mild-moderate but not severe
References (17)
- et al.
Atorva-statin-induced acute hepatitis with absence of cross-sensitivity with simvastatin
Lancet
(1999) - et al.
Acute cholestatic hepatitis associated with pravastatin
Am J Gastroenterol
(1999) - et al.
Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantationresults of a randomized cross-over trial
J Hepatol
(2001) - et al.
The Regenstrief Medical Record Systema quarter century experience
Int J Med Inform
(1999) - et al.
Medical management of hyperlipidemia/dyslipidemia
J Clin Endocrinol Metab
(2003) - et al.
Safety considerations for statins
Curr Opin Lipidol
(2002) - et al.
Hepatotoxicity of commonly used drugsnonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs
Semin Liver Dis
(2002) - et al.
Lipid lowering medication and hepatotoxicity
J Intern Med
(2001)
Cited by (382)
Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV
2024, Journal of Clinical LipidologyDietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
2024, European Journal of Internal MedicineDrug-Induced Acute-on-Chronic Liver Failure: Challenges and Future Directions
2023, Clinics in Liver DiseaseAntidiabetic potential of Gymnemic acid mediated gold nanoparticles (Gym@AuNPs) on Streptozotocin-induced diabetic rats-An implication on in vivo approach
2023, International Journal of PharmaceuticsTreatment Guidelines Overview: European Society of Cardiology/European Atherosclerosis Society Guidelines
2023, Clinical Lipidology: A Companion to Braunwald's Heart DiseaseNonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease
2023, Cardiovascular Endocrinology and Metabolism: Theory and Practice of Cardiometabolic Medicine
- ☆
Supported in part by FDA (FD-T-001756 to S.D.H.) and NIH grants (UO-1 DK 065211 to N.C.).